Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1
Year: 2012
Type: review
Source: Expert Opinion on Drug Discovery
Institution: Eli Lilly (United States)
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: exenatide, GLP-1 receptor agonists, exendin-4, type 2 diabetes, incretins, Gila monster, glucose-dependent insulin secretion, glucagon suppression, gastric emptying, satiety, beta-cell function, weight loss, pharmacokinetics, toxicology, cardiometabolic effects, hypoglycemia risk, peptide therapeutics
Open Access status: closed
OpenAlex ID: W2059228484
